Clinical Trials Sponsored by M&R Pharm

Total 106 results

R-Pharm

Completed

Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

COVID-19

Russian Federation
R-Pharm

Completed

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

Neoplasms | Advanced Solid Tumors

United States
R-Pharm

Completed

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

Solid Malignancies

United States
R-Pharm

Completed

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Breast Cancer | Metastases

Belgium, Spain, United States, Argentina, Brazil, Canada, Germany, Peru, Taiwan, United Kingdom, Italy, France, Korea, Republic of, Philippines, Thailand, Mexico, Sweden, China, Hungary, Poland, Greece, Malaysia
R-Pharm

Terminated

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (IXAMPLE2)

Endometrial Cancer

Brazil, Czech Republic, Italy, Mexico, Russian Federation, Sweden, United Kingdom, United States, Spain, Canada, Denmark, France, Peru, Belgium, Hungary, Norway, Argentina, Australia, Greece
R-Pharm

Completed

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

Neoplasms | Advanced Solid Tumors

United States
R-Pharm

Completed

A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Breast Cancer

Japan
R-Pharm

Completed

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Metastatic Breast Cancer

Italy, Turkey, Spain, France, Greece
R-Pharm

Completed

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
R-Pharm

Completed

Phase I Combination w/ Epirubicin

Metastatic Breast Cancer

Italy, France
R-Pharm

Completed

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Advanced/Metastatic Non-Small Cell Lung Cancer

Germany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
R-Pharm

Completed

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) (PIONEER)

Hepatitis C

Russian Federation
R-Pharm

Completed

Ixabepilone Administered as an Enteric Coated Formulation.

Cancer

United States
R-Pharm

Completed

A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline

Metastatic Breast Cancer

Japan
R-Pharm

Completed

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

Solid Tumors
R-Pharm

Completed

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

Breast Cancer | Metastases

United States, Netherlands, Argentina, Canada, South Africa, Mexico, Norway, Sweden, France, Germany
R-Pharm

Terminated

Phase 1 Trial of Oral Ixabepilone

Advanced Solid Tumors

United States
R-Pharm

Terminated

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer (IXTEND)

Breast Neoplasms

United States
R-Pharm
Covance; Cromos Pharma LLC

Withdrawn

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

COVID-19
R-Pharm

Completed

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Cancer | Breast Cancer

Turkey, Chile, Belgium, Portugal, Spain, Italy, United States, Argentina, Austria, Brazil, Canada, France, Germany, Singapore, South Africa, Taiwan, United Kingdom, Israel, Australia, Korea, Republic of, Russian Federation, Ireland, Netherland... and more
R-Pharm

Completed

Phase I Combination Ixabepilone + Cisplatin

Non Small Cell Lung Cancer

United States, Italy
R-Pharm

Completed

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of, Taiwan, Japan, Singapore, Hong Kong
R-Pharm

Completed

Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant

Metastatic Breast Cancer
R-Pharm

Completed

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

Metastatic Breast Cancer

Italy, United Kingdom, United States, France, Spain
R-Pharm

Completed

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
R-Pharm

Completed

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

Cancer

United States
R-Pharm

Completed

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Metastatic Breast Cancer | Triple Negative Locally Advanced Non-resectable Breast Cancer

Czech Republic, Italy, Poland, Spain, Austria, France, Greece
R-Pharm

Completed

A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy

Carcinoma, Non-small-cell Lung

United States
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

Rheumatoid Arthritis

United States, Belgium, United Kingdom
UCB BIOSCIENCES, Inc.
R-Pharm

Terminated

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
R-Pharm
MonitorCRO

Completed

Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects

Healthy

Turkey
R-Pharm
Almedis

Completed

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Healthy

Russian Federation
R-Pharm
GlaxoSmithKline

Terminated

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Locally Advanced or Metastatic Breast Cancer

United States, Italy, Australia
R-Pharm
AstraZeneca

Completed

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

COVID-19

United Arab Emirates
R-Pharm
Ascent

Completed

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Hepatic Impairment

Georgia, Russian Federation
R-Pharm
Almedis

Completed

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Healthy

Russian Federation
R-Pharm
Almedis

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Chronic Hepatitis C Genotype 1b

Russian Federation
R-Pharm Overseas, Inc.
Worldwide Clinical Trials

Not yet recruiting

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

Schnitzler Syndrome | Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)

United States
R-Pharm Overseas, Inc.
R-Pharm; Data Management 365; Cromos Pharma LLC; Keystat, LLC; K-Research

Completed

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Acute ST Segment Elevation Myocardial Infarction

United States, Russian Federation
R-Pharm Overseas, Inc.
Data Management 365; Keystat, LLC

Not yet recruiting

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Recurrent Pericarditis

United States
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 2)

Rheumatoid Arthritis

United States, Germany, Korea, Republic of, Bulgaria, Poland, Taiwan, Mexico, Hungary, Czechia, United Kingdom, Lithuania, Argentina, Brazil, Colombia, Estonia, Latvia, Russian Federation, Romania
R-Pharm International, LLC
IQVIA Pvt. Ltd; OCT Clinical Trials

Completed

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (CREDO 4)

Rheumatoid Arthritis

Korea, Republic of, United States, Germany, Hungary, Bulgaria, Poland, Taiwan, Mexico, Czechia, Argentina, United Kingdom, Belarus, Brazil, Colombia, Estonia, Latvia, Lithuania, Russian Federation
R-Pharm International, LLC
Data Management 365; K-Research, LLC

Completed

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

COVID-19

Russian Federation
R-Pharm
OCT Clinical Trials

Completed

Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

Pneumonia, Bacterial

Russian Federation
R-Pharm
US Oncology Research

Completed

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
R-Pharm
Synergy Research Inc.

Completed

Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence

Alcohol Dependence

Russian Federation, Kazakhstan
R-Pharm
Synergy Research Inc.

Completed

Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.

Overactive Bladder

Russian Federation
R-Pharm
Synergy Research Inc.

Completed

Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia

General Anaesthesia

Russian Federation
Michael M. Pham

Terminated

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

Systemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditions

United States
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials; Mene Research

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (CREDO 3)

Rheumatoid Arthritis

United States, Korea, Republic of, Germany, Czechia, Mexico, Hungary, Poland, Argentina, Brazil, Colombia, Russian Federation

3

Subscribe